Opendata, web and dolomites

NOC

Nerve-on-Chips

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NOC project word cloud

Explore the words cloud of the NOC project. It provides you a very rough idea of what is the project "NOC" about.

advantages    ooc    memories       alzheimer    human    start    organoids    turnover    subunits    economic    reconstitution    provides    conventional    drug    trillion    efficiency    vitro    ip    burden    neuron    turn    lives    65    lose    culture    predicting    financial    incidence    grow    biology    chips    models    networks    worldwide    microbrain    validating    health    subcategory    reduce    3d    individual    patent    cureor    technological    biological    agencies    2014    share    supply    compatibility    chain    animal    individuals    dimensional    simulate    life    innovative    feasibility    total    2020    organ    clients    patients    nd    founded    devastating    reconstructed    competitiveness    tri    absence       generate    society    drugs    micron    ultimately    policy    physiological    mbbt    few    licenses    visualization    worth    relatives    suffer    patented    startup    15    care    biopharmaceutical    noc    competitors    latter    clinical    biotech    nerve    types    solutions    functions    shape    million    people    microfluidic    function    diseases    time    independence    neurodegenerative    disease    coming    tissues    prevent    purchase    market    2d    assessing    improvement    expectancy    readouts   

Project "NOC" data sheet

The following table provides information about the project.

Coordinator
MICROBRAIN BIOTECH 

Organization address
address: 46 RUE CARDINET
city: PARIS
postcode: 75017
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://microbrainbiotech.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2017-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MICROBRAIN BIOTECH FR (PARIS) coordinator 50˙000.00

Map

 Project objective

Neurodegenerative diseases (“ND”) are devastating as they cause individuals to lose their memories, independence, and ultimately, their lives. In the absence of drugs able to cureor prevent start of ND, the latter are a human and financial burden for individual patients, their relativesthe health care system and society in general. The worldwide economic impact of ND is evaluated at $2 trillion a year. The incidence of ND is expected to grow in the coming few years as life expectancy increases. In 2020, over 65 million people will suffer from Alzheimer Disease worldwide (over 6.5 million in the EU).

MicroBrain Biotech is an innovative biotech startup founded in 2014. MBBT aims at offering “turn-key solutions” to biopharmaceutical research which will take the shape of microfluidic chips offering different types of reconstructed neuron networks at the micron scale. These chips are called Nerve-on-Chips (“NoC”, subcategory of Organ-on-Chips), and they simulate the function of tissues and organ subunits. Our patented NOC technology provides many advantages over other in vitro models such as conventional two-dimensional (2D) and tri-dimensional (3D) culture systems, over organoids, and over animal models: - Reduce biopharmaceutical R&D costs and increased efficiency in clinical research (improved competitiveness) - Reduce animal testing - Predicting human-relevant drug responses - Compatibility with readouts used in biology & real time visualization - Reconstitution of complex organ-level physiological functions

NOC will allow to reduce drug R&D costs by 15% which will generate a total turnover worth €30 million. MBBT’s objective is to reach a €2 million worth turnover (i.e.: 8% OOC market share) within the 3 next years. The feasibility study will allow us to ensure IP policy (improvement patent, purchase of licenses) while assessing the market (supply chain, drug agencies, competitors, clients…) and validating the technological and biological approach.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NOC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More